Invited Commentary: Evolving Management of COVID-19 Vaccine–related Axillary Adenopathy

Radiographics

HomeRadioGraphicsVol. 42, No. 7 PreviousNext Breast ImagingFree AccessInvited Commentary: Evolving Management of COVID-19 Vaccine–related Axillary AdenopathySusan Weinstein Susan Weinstein Author AffiliationsFrom the Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, 3400 Spruce St, 1 Silverstein Building, Philadelphia, PA 19104.Address correspondence to the author (email: [email protected]).Susan Weinstein Published Online:Aug 26 2022https://doi.org/10.1148/rg.220180MoreSectionsPDF ToolsImage ViewerAdd to favoritesCiteTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinked In See also the article by Zhang et al in this issue.In 2020, the world was disrupted by the impact of COVID-19, and we still continue to feel its repercussions today. We are still dealing with supply chain issues, and we continue to grapple with the impact of the Great Resignation, with a record number of people choosing to leave their jobs. Like the rest of the economy, health care was significantly impacted.During the height of the pandemic, elective surgeries and procedures were deferred, as well as routine screening examinations. At the University of Pennsylvania, the breast imaging center remained open only for patients who needed diagnostic imaging, but similar to other centers, screening was deferred during the height of the pandemic. With the reopening and resumption of mammographic screening, it was estimated that there was a deficit of almost 4 million screening episodes (1). The reason for this may be multifactorial, such as health concerns about entering a medical facility, limited access, mixed messages, and financial hardship.The pandemic led to the shutdown of the economy, with massive layoffs resulting in financial hardship for patients and loss of employer-sponsored health insurance. Health care gradually reopened with social distancing guidelines, yet the cessation of screening for months resulted in backlogs, and we have yet to close the gap. The delay in screening has also resulted in a backlog of biopsies, as patients present with more advanced cancers. The access issues have been exacerbated by a national shortage of breast imagers and technologists, as some chose to leave their professions as part of the Great Resignation.The U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for the Pfizer-BioNTech and Moderna vaccines in 2020 and the Johnson & Johnson vaccine in 2021. Soon after, reports of unilateral axillary adenopathy detected clinically and at mammography began to surface. The authors of “Axillary Lymphadenopathy in the COVID-19 Era: What the Radiologist Needs to Know” (2) expertly review the imaging findings and summarize the varying society guidelines that ensued.Various societies and groups began to issue recommendations, resulting in mixed messages to the public. Between January 2021 and March 2022, the Society of Breast Imaging, Radiological Society of North America (RSNA), and Massachusetts General Hospital each issued management guidelines (3–5). The recommendations ranged from recalling patients with unilateral adenopathy for follow-up imaging to issuing a Breast Imaging Reporting and Data System (BI-RADS) category 2 at screening, if there was a documented clinical history of ipsilateral vaccine administration. The European Society of Breast Imaging did not issue its risk-stratified recommendations until August 2021 (6).In addition to the mixed messages about management, there were mixed messages regarding the timing of the screening examination relative to the vaccine administration. Some recommended screening before administration of the first dose or waiting at least 6–12 weeks after the second dose, while others did not think that such “timing” of imaging was warranted (3–6). At the time these recommendations were made, the impact and duration of axillary adenopathy after administration of messenger RNA (mRNA)–based vaccine still needed to be better elucidated; it was all new territory.New data continue to emerge. Wolfson and colleagues (7) reported findings from the largest cohort to date. The authors reported the presence of vaccine-related lymphadenopathy as early as 1 day and as long as 71 days after vaccination. In their cohort, all four patients diagnosed with metastatic breast cancer to the axilla had suspicious mammographic findings. Short-term follow-up yielded no malignancy.On the basis of these results, the authors concluded that short-term follow-up should not be recommended for unilateral axillary adenopathy in the context of vaccine administration with no suspicious findings in the ipsilateral breast. During the study period, 407 follow-up examinations were performed. Eliminating the need for the follow-up examinations will open up much-needed examination slots, help alleviate some of the backlog, and decrease patient anxiety.As new COVID-19 variants arise, additional boosters will likely be needed. There is talk of annual boosters as new variants emerge, similar to the flu vaccine. As of now, we do not fully know the impact of each additional booster that the patient receives in regard to the degree and duration of adenopathy. Therefore, continued documentation of the vaccination date and the side of administration should be obtained from the patient for every patient undergoing mammography.The mammographic interpretation should be made in the context of this information as well as the knowledge that extended persistence of the lymphadenopathy may occur in some patients. The society guidelines, which are now better aligned, give us general guidelines on management of vaccine-related adenopathy. Thus armed with the latest scientific data, we should interpret the mammograms taking into consideration the patient’s personal history and risk factors, while minimizing harm to the patient.The author has disclosed no relevant relationships.References1. Chen RC, Haynes K, Du S, Barron J, Katz AJ. Association of cancer screening deficit in the United States with the COVID-19 pandemic. JAMA Oncol 2021;7(6):878–884. Crossref, Medline, Google Scholar2. Zhang M, Ahn RW, Hayes JC, Seiler SJ, Mootz AR, Porembka JH. Axillary Lymphadenopathy in the COVID-19 Era: What the Radiologist Needs to Know. RadioGraphics 2022;42(7):1897–1911. Link, Google Scholar3. Grimm L, Destounis S, Dogan B, et al. SBI recommendations for the management of axillary adenopathy in patients with recent COVID-19 vaccination. https://www.sbi-online.org/Portals/0/Position%20Statements/2021/SBI-recommendations-for-managing-axillary-adenopathy-post-COVID-vaccination.pdf. Published January 22, 2021. Accessed July 29, 2022. Google Scholar4. Becker AS, Perez-Johnston R, Chikarmane SA, et al. Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel. Radiology 2021;300(2):E323–E327. Link, Google Scholar5. Lehman CD, D’Alessandro HA, Mendoza DP, Succi MD, Kambadakone A, Lamb LR. Unilateral Lymphadenopathy After COVID-19 Vaccination: A Practical Management Plan for Radiologists Across Specialties. J Am Coll Radiol 2021;18(6):843–852. Crossref, Medline, Google Scholar6. Schiaffino S, Pinker K, Magni V, et al. Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging (EUSOBI). Insights Imaging 2021;12(1):119. Crossref, Medline, Google Scholar7. Wolfson S, Kim E, Plaunova A, et al. Axillary Adenopathy after COVID-19 Vaccine: No Reason to Delay Screening Mammogram. Radiology 2022;303(2):297–299. Link, Google ScholarArticle HistoryReceived: July 31 2022Accepted: Aug 3 2022Published online: Aug 26 2022Published in print: Nov 2022 FiguresReferencesRelatedDetailsAccompanying This ArticleAxillary Lymphadenopathy in the COVID-19 Era: What the Radiologist Needs to KnowAug 26 2022RadioGraphicsRecommended Articles Follow-up of COVID-19 Vaccine–related Axillary Lymphadenopathy before 12 Weeks Is UnnecessaryRadiology2022Volume: 305Issue: 1pp. 54-55Axillary Adenopathy after COVID-19 Vaccine: No Reason to Delay Screening MammogramRadiology2022Volume: 303Issue: 2pp. 297-299Breast Cancer Screening and Axillary Adenopathy in the Era of COVID-19 VaccinationRadiology2022Volume: 306Issue: 2Axillary Lymphadenopathy in the COVID-19 Era: What the Radiologist Needs to KnowRadioGraphics2022Volume: 42Issue: 7pp. 1897-1911Supplemental Screening Breast US in Women with Negative Mammographic Findings: Effect of Routine Axillary ScanningRadiology2017Volume: 286Issue: 3pp. 830-837See More RSNA Education Exhibits Common Questions and Challenging Scenarios of the Daily Practice Using the BI-RADS® AtlasDigital Posters2022Mitigating The Impact Of Coronavirus Disease (COVID-19) Vaccinations On Patients Undergoing Breast Imaging Examinations: A Multimodality Case Based Breast Imaging ReviewDigital Posters2021Calling The Shots: What Radiologists Need To Know About Axillary Lymphadenopathy In The COVID EraDigital Posters2021 RSNA Case Collection Axillary Adenopathy Secondary to HIVRSNA Case Collection2021 Post vaccination axillary adenopathyRSNA Case Collection2021Vaccination related Axillary Lymphadenopathy RSNA Case Collection2022 Vol. 42, No. 7 Metrics Altmetric Score Open AccessThis article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.PDF download

Visit paper website